Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 543434 | NSE Symbol : SUPRIYA | ISIN : INE07RO01027 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
05-Mar-2025	10-Mar-2025	Change in Other Executives	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/03/2025 inter alia to consider and approve With reference to above subject matter and pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the meeting of the Board of Directors of the Company will be held on Monday March 10 2025 at 11.30 a.m at the registered office of the Company to consider and transact the following businesses: 1. Appointment of Company Secretary and Compliance Officer of the Company; 2. Any other matter with the permission of the chair. Kindly take the above information on your records. With reference to above subject matter and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their meeting held on Monday, March 10, inter alia considered and approved the following businesses: 1. Appointment of Ms. Prachi Sathe bearing Membership No. A-70252 as Company Secretary and Compliance Officer of the Company with effect from March 10, 2025, on the basis of recommendations received from the Nomination and Remuneration Committee of the Company; 2. Any other matters incidental with the appointment of Company Secretary and Compliance Officer of the Company; Brief profile as per SEBI circular is attached. The Meeting of the Board of Directors of the Company commenced at 11.30 a.m. and concluded at 12.00 noon. Kindly take the same on record. (As Per Bse Announcement Dated on 10.03.2025)
16-Jan-2025	24-Jan-2025	Quarterly Results	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2024. Please find the attachment. Please be informed that the Board of Directors of the Company at its Meeting held on Friday, January 24, 2025, has approved the Unaudited Financial Results and appointed Directors as per attachment. (As Per BSE Announcement Dated on 24/01/2025)
21-Oct-2024	28-Oct-2024	Quarterly Results	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024 Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Monday, October 28, 2024, inter-alia considered and approved the Unaudited Financial Results for the quarter and half year ended September 30, 2024. Read less.. Please find attachemnt. (As Per BSE Announcement Dated on 28.10.2024)
03-Aug-2024	10-Aug-2024	Quarterly Results	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30 2024. Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Saturday, August 10, 2024, inter-alia, has 1. Considered and approved the Unaudited Financial Results for the Quarter ended June 30, 2024 2. Approved the additional Capital Expenditure at Ambernath site for CDMO facility. Read less.. Please find the attachment. (As Per BSE Announcement Dated on 10.08.2024)
20-May-2024	28-May-2024	Final Dividend	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31 2024 and to recommend dividend if any for the financial year ended March 31 2024. Considered and approved a dividend of Rs. 0.80 per equity shares of Rs. 2/- each (As Per BSE Announcement dated on 28.05.2024)
30-Jan-2024	07-Feb-2024	Quarterly Results	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2024 inter alia to consider and approve the Unaudited Financial Results for the quarter and nine months ended December 31 2023. Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Wednesday, February 7, 2024, inter-alia has: 1. Considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2023. 2. Approved the Capital Expenditure plan at Ambernath site for CDMO facility (As Per BSE Announcement Dated on: 07/02/2024)
27-Oct-2023	07-Nov-2023	Quarterly Results	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve the Unaudited Financial Results for the quarter and half year ended September 30 2023. Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Tuesday, November 7, 2023, inter-alia considered and approved the Unaudited Financial Results for the Quarter and half year ended September 30, 2023. Please find attachment. (As Per BSE Announcement Dated on 07/11/2023)
27-Jul-2023	03-Aug-2023	Quarterly Results	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30 2023 Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Thursday, August 3, 2023, inter-alia, has considered and approved the Unaudited Financial Results for the Quarter ended June 30, 2023. We hereby enclose the following: 1. Copy of the Unaudited Financial Results of the Company for the quarter ended June 30, 2023 along with the Limited Review report issued by Statutory Auditor; (As per BSE Announcement Dated on 03/08/2023)
19-May-2023	26-May-2023	Accounts	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2023 inter alia to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31 2023 and to recommend dividend if any for the financial year ended March 31 2023. This is further to inform you that with reference to our letter dated March 30 2023 and in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 as amended from time to time and the Companys Code of Conduct for Prevention of Insider Trading the Trading Window for dealing in the securities of the Company shall continue to remain closed till 48 hours after announcement of Audited Financial Results for the quarter and year ended March 31 2023. Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, May 26, 2023, recommended the Final Dividend of Rs. 0.60 per equity share (face value of Rs. 2/- each) subject to approval of shareholders in the ensuing Annual General Meeting. Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, May 26, 2023, as attached (As Per BSE Announcement Dated on 26.05.2023)
06-Feb-2023	14-Feb-2023	Quarterly Results	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2022. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Tuesday, February 14, 2023, inter-alia, has: 1. Considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2022. We hereby enclose the following: 1. Copy of the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022 along with the Limited Review report issued by Statutory Auditor; (As Per BSE Announcement Dated on 14.02.2023)
23-Jan-2023	23-Jan-2023	Change in Directors	Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at their meeting held on January 23, 2023 have appointed Mr. Manoj Deo Dorlikar as an Additional Director in the capacity of Whole Time Director of the Company w.e.f. January 23, 2023 for a period of three years, subject to approval of the shareholders and the Central Government as may be applicable
02-Nov-2022	10-Nov-2022	Quarterly Results	Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2022. Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Thursday, November 10, 2022, inter-alia, has: 1. Considered and approved the Unaudited Financial Results for the Quarter and six months ended September 30, 2022. 2. Approved appointment of M/s. DSM & Associates, Practising Company Secretaries as Secretarial Auditor for the financial year 2022-23; 3. Approved appointment of M/s. Nair's & Panicker's, Audit & Advisory Services, as Internal Auditor for the financial year 2022-23; (As per BSE Announcement Dated on 10/11/2022) We hereby enclose the following: 1. Copy of the Revised Unaudited Financial Results of the Company for the quarter and six months ended September 30, 2022 along with the Limited Review report issued by Statutory Auditor; (As Per BSE Announcement dated on 11.11.2022) With reference to the above captioned subject, please find enclosed newspaper advertisement published in Financial Express and Loksatta on Saturday, November 12, 2022, containing extract of Unaudited Financial Results for the quarter and six months ended September 30, 2022. (As Per BSE Announcement Dated on 14.11.2022)
27-Sep-2022	27-Sep-2022	Change in Directors	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Dr. Shireesh Ambhaikar, Chief Executive Officer and a Key Managerial Personnel of the company, has resigned from the position due to his personal reasons and requested, inter alia, for acceptance of his resignation and relieving him by September 30, 2022 and which has been accepted by the Board in its meeting held today i.e. September 27, 2022. The Board has in its meeting held today i.e. September 27, 2022 approved the appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of the Company, who will be joining on October 3, 2022 to take Supriya on the next phase of its growth journey. (As Per BSE Announcement dated on 27.09.2022)
05-Aug-2022	12-Aug-2022	Quarterly Results	Quarterly Results Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2022 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2022. This is further to inform you that with reference to our letter dated June 29, 2022 and in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company's Code of Conduct for Prevention of Insider Trading, the ''Trading Window' for dealing in the securities of the Company shall continue to remain closed till 48 hours after announcement of Unaudited Financial Results for the quarter ended June 30, 2022. Kindly take the above said information on your records. Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, August 12, 2022, inter-alia, has: 1. Considered and approved the Unaudited Financial Results for the Quarter ended June 30, 2022. 2. Recommended re-appointment of M/s. Kakaria & Associates LLP, Chartered Accountants (Firm Registration No. 104558W/W100601) as the Statutory Auditors of the Company, for second term of five years from the conclusion of the ensuing 14th AGM till the conclusion of the 19th AGM to be held in the year 2027, subject to approval of the members at the ensuing 14th AGM.. (As per BSE Announcement Dated on 12/08/2022) With reference to the above captioned subject, please find enclosed newspaper advertisement published in Financial Express and Loksatta on Saturday, August 13, 2022, containing extract of Unaudited Financial Results for the quarter ended June 30, 2022. You are requested to kindly take the same on record. (As Per BSE Announcement Dated on 13/08/2022)
13-May-2022	20-May-2022	Final Dividend	Final Dividend & Audited Results Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 ,inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2022 and to recommend dividend, if any, for the financial year ended March 31, 2022. This is further to inform you that with reference to our letter dated March 30, 2022 and in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company's Code of Conduct for Prevention of Insider Trading, the ''Trading Window' for dealing in the securities of the Company shall continue to remain closed till 48 hours after announcement of Audited Financial Results for the quarter and year months ended March 31, 2022. Kindly take the above said information on your records. The Board at its Meeting held today recommended the Final Dividend of Rs. 0.60 per equity share (face value of Rs. 2/- each) subject to approval of shareholders in the ensuing Annual General Meeting. Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, May 20, 2022, inter-alia, has: 1. Considered and approved the Audited Financial Results for the Quarter and year ended March 31, 2022. 2. Recommended the Final Dividend of Rs. 0.60 per equity share (face value of Rs. 2/- each) subject to approval of shareholders in the ensuing Annual General Meeting. The Financials Results will be published in newspapers as required under the Listing Regulations. The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 04:30 p.m. Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, May 20, 2022, inter-alia, has: 1. Considered and approved the Audited Financial Results for the Quarter and year ended March 31, 2022. 2. Recommended the Final Dividend of Rs. 0.60 per equity share (face value of Rs. 2/- each) subject to approval of shareholders in the ensuing Annual General Meeting. (As Per BSE Announcement Dated on 20.05.2022)

1 2

LOGIN HERE

Supriya Lifescience Ltd

Board Meeting